SPH-5030 clinical trials
Also written SPH5030.
How each study uses SPH-5030 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SPH-5030 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SPH5030
- 2
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SPH-5030.
- Dec 2026SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsEarly Phase 1 · Shanghai Pharmaceuticals Holding Co., Ltd
- Dec 2026A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.Phase 2 · Shanghai Pharmaceuticals Holding Co., Ltd
Studies
Open first, then newest update. How each study uses SPH-5030 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- SPH5030 Tablets in Subjects With Advanced Her2-positive Solid TumorsRecruitingEarly Phase 1Shanghai Pharmaceuticals Holding Co., LtdNCT05245058Written as SPH5030 tablets
- A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.RecruitingPhase 2Shanghai Pharmaceuticals Holding Co., LtdNCT06434597Written as SPH5030
- A Food Effect Study of SPH5030 Tablets.CompletedPhase 1Shanghai Pharmaceuticals Holding Co., LtdNCT06372223Written as SPH5030
Codes
What other systems call SPH-5030 · ClinicalTrials.gg INT016474
- UNII (FDA) EP2QR4P7ZLSPH-5030One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EP2QR4P7ZL | SPH-5030 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.